Compound Detail
CHEMBL565
CLOFIBRATE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL565 |
| Name | CLOFIBRATE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | KNHUKKLJHYUCFP-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
| Active Moiety | CHEMBL683 |
4
Targets
18
Activities
4
Assay Types
2
PK Parameters
20
Publications
10
Known Names
5
Indications
1
Mechanisms
Molecular Properties
242.7
MW (Da)
3.06
ALogP
3
HBA
0
HBD
35.5
PSA (Ų)
0.76
QED
0
Ro5 Violations
4
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1967 |
| Availability | Withdrawn |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Peroxisome proliferator-activated receptor alpha agonist | AGONIST | Peroxisome proliferator-activated receptor alpha | ✓ | ✓ |
Indications
Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Infarction Myocardial Ischemia
ATC Classification
C10AB01
clofibrate
Level 1: CARDIOVASCULAR SYSTEM
Level 2: LIPID MODIFYING AGENTS
Drug Warnings
Withdrawn
vascular toxicity
Increases the incidence of gallstones and cholecystitis, drug-induced cardiac arrhythmias, cardiomegaly, angina, claudication and thromboembolic phenomena. It also enhances the effects and toxicity of...
Withdrawn
carcinogenicity
Increases the incidence of gallstones and cholecystitis, drug-induced cardiac arrhythmias, cardiomegaly, angina, claudication and thromboembolic phenomena. It also enhances the effects and toxicity of...
Withdrawn
General Warning
Increases the incidence of gallstones and cholecystitis, drug-induced cardiac arrhythmias, cardiomegaly, angina, claudication and thromboembolic phenomena. It also enhances the effects and toxicity of...
Withdrawn
General Warning
Increased mortality associated with use
Withdrawn
cardiotoxicity
Increases the incidence of gallstones and cholecystitis, drug-induced cardiac arrhythmias, cardiomegaly, angina, claudication and thromboembolic phenomena. It also enhances the effects and toxicity of...
Withdrawn
General Warning
Increases the incidence of gallstones and cholecystitis, drug-induced cardiac arrhythmias, cardiomegaly, angina, claudication and thromboembolic phenomena. It also enhances the effects and toxicity of...
Withdrawn
cardiotoxicity
Increases the incidence of gallstones and cholecystitis, drug-induced cardiac arrhythmias, cardiomegaly, angina, claudication and thromboembolic phenomena. It also enhances the effects and toxicity of...
Withdrawn
General Warning
Increases the incidence of gallstones and cholecystitis, drug-induced cardiac arrhythmias, cardiomegaly, angina, claudication and thromboembolic phenomena. It also enhances the effects and toxicity of...
Withdrawn
General Warning
Increases the incidence of gallstones and cholecystitis, drug-induced cardiac arrhythmias, cardiomegaly, angina, claudication and thromboembolic phenomena. It also enhances the effects and toxicity of...
Activity Summary
Kd 8 meas. best 5.22
EC50 7 meas. best 4.3
IC50 2 meas. best 4.22
Ki 1 meas. best 5.16
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Fatty acid-binding protein, liver CHEMBL5738 | Kd | 5.22 | 5.0738 | 6000.0 | 8 |
| Fatty acid-binding protein, liver CHEMBL5738 | Ki | 5.16 | 5.16 | 6920.0 | 1 |
| Peroxisome proliferator-activated receptor alpha CHEMBL2128 | EC50 | 4.3 | 4.3 | 50000.0 | 1 |
| Peroxisome proliferator-activated receptor alpha CHEMBL239 | EC50 | 4.26 | 4.26 | 55000.0 | 3 |
| Bile salt export pump CHEMBL6020 | IC50 | 4.22 | 4.185 | 60000.0 | 2 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 157597.24 | ng.hr.mL-1 | Homo sapiens |
| F | 95.0 | % | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine